Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Piroxicam-containing products

Executive Summary

Piroxicam-containing products: FDA will seek the advice of the Arthritis Advisory Committee in a future meeting to determine whether the agency should remove drug products containing the non-steroidal anti-inflammatory drug from the market, an April 12 letter from Center for Drug Evaluation & Research Director Janet Woodcock, MD, states. The letter is a tentative response to a Public Citizen Health Research Group citizen petition requesting the removal of piroxicam-containing drug products because of gastrointestinal problems associated with their use...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026132

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel